Vaccination for Patients Receiving Dialysis
© 2023 The Authors..
Vaccinating patients receiving dialysis may prevent morbidity and mortality in this vulnerable population. The National Forum of End-Stage Renal Disease Networks (the Forum) published a revised vaccination toolkit in 2021 to update evidence and recommendations on vaccination for patients receiving dialysis. Significant changes in the last 10 years include more data supporting the use of a high-dose influenza vaccine, the introduction of the Heplisav-B vaccine for hepatitis B, and changes in pneumococcal vaccines, including the approval of the PCV15 and PCV20 to replace the PCV13 and PPSV23 vaccines. Additional key items include the introduction of vaccines against severe acute respiratory syndrome coronavirus 2, the virus that causes coronavirus disease 2019 (COVID-19), and a new vaccine to prevent respiratory syncytial virus disease. Historically, influenza and pneumococcal vaccinations were routinely administered by dialysis facilities, and because of possible risks of hematogenous spread of hepatitis B, dialysis providers often have detailed hepatitis B vaccine protocols. In March 2021, COVID-19 vaccines were made available for dialysis facilities to administer, although with the end of the public health emergency, vaccine policies by dialysis facilities against COVID-19 remains uncertain. The respiratory syncytial virus vaccine was authorized in 2023, and how dialysis facilities will approach this vaccine also remains uncertain. This review summarizes the Forum's vaccination toolkit and discusses the role of the dialysis facility in vaccinating patients to reduce the risk of severe infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Kidney medicine - 6(2024), 3 vom: 27. März, Seite 100775 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sam, Ramin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dialysis |
|---|
| Anmerkungen: |
Date Revised 05.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.xkme.2023.100775 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369249348 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369249348 | ||
| 003 | DE-627 | ||
| 005 | 20240305232728.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240304s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xkme.2023.100775 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1317.xml |
| 035 | |a (DE-627)NLM369249348 | ||
| 035 | |a (NLM)38435066 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sam, Ramin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccination for Patients Receiving Dialysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. | ||
| 520 | |a Vaccinating patients receiving dialysis may prevent morbidity and mortality in this vulnerable population. The National Forum of End-Stage Renal Disease Networks (the Forum) published a revised vaccination toolkit in 2021 to update evidence and recommendations on vaccination for patients receiving dialysis. Significant changes in the last 10 years include more data supporting the use of a high-dose influenza vaccine, the introduction of the Heplisav-B vaccine for hepatitis B, and changes in pneumococcal vaccines, including the approval of the PCV15 and PCV20 to replace the PCV13 and PPSV23 vaccines. Additional key items include the introduction of vaccines against severe acute respiratory syndrome coronavirus 2, the virus that causes coronavirus disease 2019 (COVID-19), and a new vaccine to prevent respiratory syncytial virus disease. Historically, influenza and pneumococcal vaccinations were routinely administered by dialysis facilities, and because of possible risks of hematogenous spread of hepatitis B, dialysis providers often have detailed hepatitis B vaccine protocols. In March 2021, COVID-19 vaccines were made available for dialysis facilities to administer, although with the end of the public health emergency, vaccine policies by dialysis facilities against COVID-19 remains uncertain. The respiratory syncytial virus vaccine was authorized in 2023, and how dialysis facilities will approach this vaccine also remains uncertain. This review summarizes the Forum's vaccination toolkit and discusses the role of the dialysis facility in vaccinating patients to reduce the risk of severe infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Dialysis | |
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 4 | |a influenza | |
| 650 | 4 | |a pneumococcus | |
| 650 | 4 | |a vaccination | |
| 700 | 1 | |a Rankin, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Ulasi, Ifeoma |e verfasserin |4 aut | |
| 700 | 1 | |a Frantzen, Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Nitsch, Dorothea |e verfasserin |4 aut | |
| 700 | 1 | |a Henner, David |e verfasserin |4 aut | |
| 700 | 1 | |a Molony, Donald |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, John |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Agarwal, Sanjay Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Atkinson, Ralph |e verfasserin |4 aut | |
| 700 | 1 | |a Landry, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Pastan, Stephen O |e verfasserin |4 aut | |
| 700 | 1 | |a Kalantar-Zadeh, Kamyar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney medicine |d 2019 |g 6(2024), 3 vom: 27. März, Seite 100775 |w (DE-627)NLM303572787 |x 2590-0595 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2024 |g number:3 |g day:27 |g month:03 |g pages:100775 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xkme.2023.100775 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2024 |e 3 |b 27 |c 03 |h 100775 | ||